JP2018538302A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538302A5
JP2018538302A5 JP2018531210A JP2018531210A JP2018538302A5 JP 2018538302 A5 JP2018538302 A5 JP 2018538302A5 JP 2018531210 A JP2018531210 A JP 2018531210A JP 2018531210 A JP2018531210 A JP 2018531210A JP 2018538302 A5 JP2018538302 A5 JP 2018538302A5
Authority
JP
Japan
Prior art keywords
alkyl
oligomer
peptide
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018531210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538302A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/066595 external-priority patent/WO2017106304A1/en
Publication of JP2018538302A publication Critical patent/JP2018538302A/ja
Publication of JP2018538302A5 publication Critical patent/JP2018538302A5/ja
Pending legal-status Critical Current

Links

JP2018531210A 2015-12-15 2016-12-14 ペプチドオリゴヌクレオチド複合体 Pending JP2018538302A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267723P 2015-12-15 2015-12-15
US62/267,723 2015-12-15
PCT/US2016/066595 WO2017106304A1 (en) 2015-12-15 2016-12-14 Peptide oligonucleotide conjugates

Publications (2)

Publication Number Publication Date
JP2018538302A JP2018538302A (ja) 2018-12-27
JP2018538302A5 true JP2018538302A5 (cg-RX-API-DMAC7.html) 2020-01-30

Family

ID=59057789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531210A Pending JP2018538302A (ja) 2015-12-15 2016-12-14 ペプチドオリゴヌクレオチド複合体

Country Status (15)

Country Link
US (2) US20190030176A1 (cg-RX-API-DMAC7.html)
EP (1) EP3389719B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018538302A (cg-RX-API-DMAC7.html)
KR (1) KR20180088874A (cg-RX-API-DMAC7.html)
CN (1) CN108472504A (cg-RX-API-DMAC7.html)
AR (1) AR107220A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016372026A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018012237A2 (cg-RX-API-DMAC7.html)
CA (1) CA3006748A1 (cg-RX-API-DMAC7.html)
EA (1) EA201891419A1 (cg-RX-API-DMAC7.html)
ES (1) ES2901772T3 (cg-RX-API-DMAC7.html)
IL (2) IL259587A (cg-RX-API-DMAC7.html)
MX (1) MX2018007307A (cg-RX-API-DMAC7.html)
TW (1) TWI740866B (cg-RX-API-DMAC7.html)
WO (1) WO2017106304A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551986A (ja) 2019-10-16 2022-12-14 ザ・ブロード・インスティテュート・インコーポレイテッド 修飾筋肉標的化組成物
US12668814B2 (en) 2020-07-22 2026-06-30 The Broad Institute, Inc. Engineered muscle targeting compositions
KR102530865B1 (ko) * 2020-09-09 2023-05-10 연세대학교 산학협력단 자기조립 고리형 펩티드-올리고뉴클레오티드 복합체 및 이의 제조방법
WO2023034515A2 (en) * 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
WO2023070086A1 (en) * 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
EP4554961A2 (en) 2022-07-14 2025-05-21 The Broad Institute, Inc. Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
WO2025155923A1 (en) 2024-01-17 2025-07-24 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025217174A1 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
WO2025217163A2 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Novel aav capsids binding to human cd59
WO2026107393A2 (en) 2024-11-14 2026-05-21 The Broad Institute, Inc. Aav capsid modifications that reduce immunogenicity

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン,ジエ−ムス ポリヌクレオチド測定試薬と方法
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2004500438A (ja) * 2000-04-14 2004-01-08 アルニス バイオサイエンシーズ, インコーポレイテッド 高親和性のペプチド含有ナノ粒子
WO2002042259A2 (en) * 2000-11-27 2002-05-30 University Of Maryland, Baltimore Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid
EP1679960B1 (en) * 2003-11-07 2009-05-06 VIB vzw Transgenic amphibian models for lymphatic vessel development
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
CA2629664A1 (en) * 2005-11-17 2007-08-02 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
EP1968643A2 (en) * 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
JP2011520108A (ja) * 2008-04-30 2011-07-14 ノバルティス アーゲー 病原性配座異性体についてのアッセイ
CN103154009B (zh) * 2010-09-30 2015-06-10 日本新药株式会社 吗啉基核酸衍生物
AU2012223237A1 (en) * 2011-03-02 2013-05-02 Groove Biopharma Corporation Enhanced biodistribution of oligomers
KR20140097398A (ko) * 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
US10111962B2 (en) * 2012-09-25 2018-10-30 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
HK1220154A1 (zh) * 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
MX2017011004A (es) * 2015-02-27 2018-02-09 Sarepta Therapeutics Inc Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida.

Similar Documents

Publication Publication Date Title
JP2020537654A5 (cg-RX-API-DMAC7.html)
JP2018509143A5 (cg-RX-API-DMAC7.html)
JP2020022483A5 (cg-RX-API-DMAC7.html)
JP2021090458A5 (cg-RX-API-DMAC7.html)
JP2021182946A5 (cg-RX-API-DMAC7.html)
HRP20231431T1 (hr) Peptidno oligonukleotidni konjugati
JP2016533761A5 (cg-RX-API-DMAC7.html)
EP0719272B1 (en) Pyrimidine derivatives for labeled binding partners
JP5271913B2 (ja) 化合物
JP2020525502A5 (cg-RX-API-DMAC7.html)
JP2009538829A5 (cg-RX-API-DMAC7.html)
JP2021074021A5 (cg-RX-API-DMAC7.html)
RU2005118421A (ru) 2'-разветвленные нуклеозиды и мутация flaviviridae
JP2025509438A5 (cg-RX-API-DMAC7.html)
JP2019514426A5 (cg-RX-API-DMAC7.html)
JP2019529406A5 (cg-RX-API-DMAC7.html)
RU2006109491A (ru) Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств
JP2018530560A5 (cg-RX-API-DMAC7.html)
CN101415719A (zh) 生产2’-脱氧-β-L-核苷的方法
WO2014175974A2 (en) Artificial nucleic acids
WO2014124430A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2023546369A5 (cg-RX-API-DMAC7.html)
CN101310021A (zh) 作为抗病毒剂的修饰的4’-核苷
JP2011521930A5 (cg-RX-API-DMAC7.html)
AR127325A1 (es) Métodos y composiciones para el tratamiento de la enfermedad renal poliquística